Smith & Nephew, the medical equipment specialist reports group revenue for full year 2017 of $4,765m, an increase of 3% on an underlying basis, in line with guidance.
The company also shows that full year dividend was up 14% to 35.0¢ per share.
Commenting on the latest figures, Olivier Bohuon, Chief Executive Officer of Smith & Nephew, said: "We delivered on our promises to improve the top and bottom line in 2017. Our Knee Implants franchise delivered a standout performance and we returned to double-digit growth in the Emerging Markets."
He added: “Our healthy balance sheet, good cash generation and increased dividend demonstrate the robust foundations underpinning our business. "In 2018 I expect Smith & Nephew to build on 2017 by delivering another year of improved performance driven by our strong product portfolio and pipeline of innovative products.
"Looking further ahead, our greater focus on commercial execution gives us confidence we will outgrow our markets and the new APEX programme supports our expectation of improved trading profit margin."
In its guidance for 2018, Smith & Nephew expects revenue to increase 3%-4% underlying (around 7%-8% reported). Trading profit margin is expected to improve by a further 30-70bps.